# EDGAR Filing Document

**Accession Number:** 0001865127
**File Stem:** 0001213900-23-012576
**Filing Date:** 2023-2
**Character Count:** 10375
**Document Hash:** 752682026c14511bef1407fa5f9e9f4b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-012576.hdr.sgml**: 20230217

**ACCESSION NUMBER**: 0001213900-23-012576

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230216

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230217

**DATE AS OF CHANGE**: 20230217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lucy Scientific Discovery, Inc.
- **CENTRAL INDEX KEY:** 0001865127
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41616
- **FILM NUMBER:** 23640176

**BUSINESS ADDRESS:**
- **STREET 1:** 301-1321 BLANSHARD STREET
- **CITY:** VICTORIA
- **STATE:** A1
- **ZIP:** V8W 0B6
- **BUSINESS PHONE:** 778-410-5195

**MAIL ADDRESS:**
- **STREET 1:** 301-1321 BLANSHARD STREET
- **CITY:** VICTORIA
- **STATE:** A1
- **ZIP:** V8W 0B6

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 16, 2023**

**Lucy Scientific Discovery Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **British Columbia, Canada** | **001-41616** | **Not Applicable** |
| (State or other jurisdiction of<br> incorporation or organization) | (Commission File Number) | (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **301-1321 Blanshard Street<br> Victoria, British Columbia, Canada** | **V8W 0B6** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(778) 410-5195**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Shares, no par value | LSDI | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01** **Other Events**

On February 16, 2023, Lucy Scientific Discovery Inc. (the "***Company***") issued a press release announcing that it has filed an amendment to its current Dealer's License with Health Canada to add cocaine and heroin, among others to the list of approved substances that it is authorized to manufacture. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01** **Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press release of Lucy Scientific Discovery Inc., dated February 16, 2023](ea173857ex99-1_lucyscien.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Lucy Scientific Discovery** | **Lucy Scientific Discovery** |
| Date: February 17, 2023 | By: | /s/ Christopher McElvany |
|  | Name: | *Christopher McElvany* |
|  | Title: | *President and Chief Executive Officer* |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

Lucy Scientific Discovery Files Amendment with Health Canada to<br> Expand its List of Controlled Substances to Include Cocaine and <br> Heroin; This Expansion Represents an Effort to Supply Harm <br> Reduction Programs Around the World

VICTORIA, British Columbia, February 16, 2023 — Lucy Scientific Discovery Inc. ("Lucy" or the "Company") [NASDAQ:LSDI], an early-stage psychedelics manufacturing company that is focused on becoming the premier research, development, and manufacturing organization for the emerging psychotropics-based medicines industry, announced today that it has filed an amendment to its current Dealer's License with Health Canada to add cocaine and heroin, among others to the list of approved substances that it is authorized to manufacture.

The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options. Currently, Lucy focuses on the development of psychedelic drugs for research purposes and hopes to supply safe access programs in the future. The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B.

"We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States," said Chris McElvany, the Company's CEO. "It's time to realize that the failed war on drugs has caused additional harm to the masses worldwide, and harm reduction programs will lead to less death and more treatment options in the long term."

Following its IPO, Lucy believes that it is well-positioned to continue positively impacting the field of psychedelic medicine.

**About Lucy Scientific Discovery Inc.**

Lucy Scientific Discovery Inc. [NASDAQ:LSDI] an early-stage psychedelics manufacturing company that is focused on becoming the premier research, development, and manufacturing organization for the emerging psychedelics-based medicines industry. Lucy maintains a Controlled Drugs and Substances Dealer's License under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), more commonly known as a Dealer's License, that was issued to Lucy by Health Canada's Office of Controlled Substances. This Dealer's License authorizes the Company to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors.

For more information about the Company, please visit **https://www.lucyscientific.com/**

**Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements concerning the Company's business, operations and financial performance, as well as the Company's plans, objectives and expectations for its business operations and financial and condition. These forward-looking statements relate to future events or to the Company's future financial performance and involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company's control, and may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "should," "expect," "plan," "aim," "seek," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "forecast," "potential" or "continue" or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. These and other risks and uncertainties are described more fully in the "Risk Factors" section of our most recent registration statement on Form S-1 that was filed with the Securities and Exchange Commission, a copy of which is available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and the Company's actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

**Media Contact:**

Lucas Wentworth

Lucas@NisonCo.com

NisonCo Public Relations

**Investor Contact Information:**

Addo Investor Relations<br> lucyscientific@addo.com